• HighLife closed a $90+ million (€80 million) private financing round, with Capricorn Partners joining as a new investor.
• HighLife is a MedTech company developing transcatheter solutions for structural heart disease, centered on a transcatheter mitral valve replacement system.
• Proceeds earmarked to start a US pivotal study, accelerate commercial expansion across Europe, support broader long-term growth.
• Financing followed CE Mark clearance in January for its TMVR system, enabling a limited European market release.
• HighLife also secured CE Mark clearance in July for its next-generation Clarity Valve, designed to reduce LVOT obstruction risk.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capricorn Partners NV published the original content used to generate this news brief on September 22, 2026, and is solely responsible for the information contained therein.